BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

571 related articles for article (PubMed ID: 15914316)

  • 1. Imbalance of NKG2D and its inhibitory counterparts: how does tumor escape from innate immunity?
    Zhang C; Zhang J; Wei H; Tian Z
    Int Immunopharmacol; 2005 Jul; 5(7-8):1099-111. PubMed ID: 15914316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells.
    Zhang C; Zhang J; Sun R; Feng J; Wei H; Tian Z
    Int Immunopharmacol; 2005 Jun; 5(6):1057-67. PubMed ID: 15829421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
    Song H; Kim J; Cosman D; Choi I
    Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
    Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
    Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NKG2D and Related Immunoreceptors.
    Strong RK; McFarland BJ
    Adv Protein Chem; 2004; 68():281-312. PubMed ID: 15500864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
    Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
    Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia.
    Romanski A; Bug G; Becker S; Kampfmann M; Seifried E; Hoelzer D; Ottmann OG; Tonn T
    Exp Hematol; 2005 Mar; 33(3):344-52. PubMed ID: 15730858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UL16 binding proteins.
    Cao W; He W
    Immunobiology; 2004; 209(3):283-90. PubMed ID: 15518340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK cells and cancer immunosurveillance.
    Waldhauer I; Steinle A
    Oncogene; 2008 Oct; 27(45):5932-43. PubMed ID: 18836474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How NKG2D ligands trigger autoimmunity?
    Caillat-Zucman S
    Hum Immunol; 2006 Mar; 67(3):204-7. PubMed ID: 16698443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innate immune recognition and suppression of tumors.
    Hayakawa Y; Smyth MJ
    Adv Cancer Res; 2006; 95():293-322. PubMed ID: 16860661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKG2D ligands in tumor immunity.
    Nausch N; Cerwenka A
    Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages.
    Diefenbach A; Jamieson AM; Liu SD; Shastri N; Raulet DH
    Nat Immunol; 2000 Aug; 1(2):119-26. PubMed ID: 11248803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of the NKG2D receptor for tumor immunity.
    Coudert JD; Held W
    Semin Cancer Biol; 2006 Oct; 16(5):333-43. PubMed ID: 16914326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NKG2D and cytotoxic effector function in tumor immune surveillance.
    Hayakawa Y; Smyth MJ
    Semin Immunol; 2006 Jun; 18(3):176-85. PubMed ID: 16675266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation.
    Gilfillan S; Ho EL; Cella M; Yokoyama WM; Colonna M
    Nat Immunol; 2002 Dec; 3(12):1150-5. PubMed ID: 12426564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D.
    Zhang C; Zhang J; Niu J; Zhou Z; Zhang J; Tian Z
    Hum Immunol; 2008 Aug; 69(8):490-500. PubMed ID: 18619507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural killer cell signaling pathways.
    Vivier E; Nunès JA; Vély F
    Science; 2004 Nov; 306(5701):1517-9. PubMed ID: 15567854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NKG2D ligands: key targets of the immune response.
    González S; López-Soto A; Suarez-Alvarez B; López-Vázquez A; López-Larrea C
    Trends Immunol; 2008 Aug; 29(8):397-403. PubMed ID: 18602338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosomes and the MICA-NKG2D system in cancer.
    Clayton A; Tabi Z
    Blood Cells Mol Dis; 2005; 34(3):206-13. PubMed ID: 15885603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.